Research across Urologic Neoplasms
Related studies from across the Urologic Neoplasms family.
Comparative Efficacy of Immunotherapy Combinations in Advanced Renal Cell Carcinoma Management
New analysis compares immunotherapy combinations for advanced renal cell carcinoma
A network meta-analysis evaluates diverse immunotherapy combinations for advanced renal cell carcinoma, highlighting specific survival benef…
A large review of over 6,000 patients identifies specific immunotherapy combinations that may improve survival for those with advanced kidne…
Immune ecotypes may offer more refined patient stratification for ccRCC than current biomarkers
Immune Ecotypes May Guide Kidney Cancer Treatment
This mini review explores the use of immune ecotypes to identify treatment-responsive profiles in patients with advanced clear cell renal ce…
New review proposes four immune subtypes in kidney cancer that could explain why some patients respond to immunotherapy and others don't.
High PTTG1 expression correlates with poorer survival and advanced disease in various solid tumors
High levels of PTTG1 protein linked to worse cancer outcomes
This meta-analysis of 22 studies from 21 articles analyzed the prognostic value of PTTG1 expression across multiple solid tumors. High PTTG1…
A review of 22 studies shows that high levels of the PTTG1 protein are linked to shorter survival times in several types of solid tumors.
Spontaneous regression observed in a patient with cystic renal cell carcinoma
Kidney tumor shows spontaneous regression before surgery for diagnosis
A case report describes a patient with a cystic mass in the left kidney that exhibited spontaneous regression following an initial period of…
A rare case of kidney cancer showed unexpected shrinking before surgery, highlighting why early intervention is vital for diagnosing complex…
Fianlimab plus cemiplimab showed objective response rates of 20% to 33% in advanced solid tumors during a Phase 1 study.
Early trial shows new cancer drug combo helps some patients with advanced disease
This Phase 1, first-in-human dose-expansion study evaluated fianlimab 1600 mg plus cemiplimab 350 mg in patients with advanced non-small cel…
A new drug combination helped some patients with advanced lung, kidney, head and neck, or skin cancer shrink their tumors in early testing.
ADRB1 and ADRB2 antihypertensive target perturbations associated with increased clear cell renal cell carcinoma risk
Genetic markers linked to blood pressure drugs raise kidney cancer risk
This meta-analysis of Mendelian randomization and colocalization analyses found that genetic perturbations equivalent to antihypertensive dr…
Genetic data suggests certain blood pressure targets may increase clear cell renal cell carcinoma risk, a finding that warrants attention fo…
Percutaneous thermal ablation shows higher local recurrence than robot-assisted partial nephrectomy for localized renal cell carcinoma
Meta-analysis shows higher local recurrence risk with thermal ablation for kidney cancer
This systematic review and meta-analysis of 2,516 patients with localized renal cell carcinoma compared percutaneous thermal ablation to rob…
A large analysis of kidney cancer treatments found thermal ablation had higher local recurrence rates than partial nephrectomy, though overa…
Angiogenic ccRCC tumors show higher pancreatic metastasis rate in phase II trial
Pancreatic Metastases Predict Better Sunitinib Response in Kidney Cancer
This phase II RCT of 305 treatment-naive ccRCC patients found that angiogenic tumors had a higher rate of pancreatic metastases (21% vs. 6.9…
Kidney tumors with certain genetic patterns are more likely to spread to the pancreas. Patients with these pancreatic metastases respond bet…
FDA approves OPDIVO QVANTIG for multiple advanced cancer indications including renal cell carcinoma and melanoma
FDA approves subcutaneous nivolumab combination for multiple advanced cancers
This FDA approval document grants authorization for OPDIVO QVANTIG, a subcutaneous combination of nivolumab and hyaluronidase, for specified…
The FDA has approved a new subcutaneous form of nivolumab for several advanced cancers, offering a more convenient treatment option for elig…
Early time-of-day immune checkpoint inhibitor administration improves overall survival in advanced solid tumors
Cancer Patients Live Longer When Immunotherapy Starts Early in Day
This systematic review and meta-analysis evaluated 6129 patients with advanced solid tumors receiving immune checkpoint inhibitors. Earlier …
• Morning immunotherapy shots link to longer survival for advanced cancers • Helps patients fighting lung stomach kidney and other tough can…
Kidney-directed SBRT shows modest renal function decline in inoperable patients
Small study shows kidney function drops after radiation for hard-to-treat tumors
This prospective phase 2 single-arm trial evaluated kidney-directed SBRT in 30 patients with primary or metastatic renal tumors who were med…
Radiation to treat kidney tumors may lower kidney function over two years, even when surgery is not an option.
Meta-analysis shows active surveillance and ablative therapy for small renal masses have comparable cancer-specific survival
Active surveillance vs ablation for small kidney tumors: what works?
This systematic review and meta-analysis evaluates active surveillance (AS) versus ablative therapy (AT) for patients with small renal masse…
For small kidney tumors, ablation may boost survival, but cancer-specific death risk is similarly low with either approach.